Expertise in
7
conditions

Dr. Margaret O'donnell

Hematology
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
Expertise in
7
conditions
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 

Overview

Margaret O'donnell is a Hematologist practicing medicine in Duarte, California.

Dr. O'donnell is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 26 peer reviewed articles and participating in 3 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

City of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, Duarte, CA 91010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug, Other, Biological
Study Drugs: Cyclophosphamide, Vincristine sulfate, Prednisone, Inotuzumab ozogamicin
Study Phase: Phase 1
View 2 Less Clinical Trials

26 Total Publications

Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
Cytokine gene polymorphisms are associated with response to blinatumomab in B-cell acute lymphoblastic leukemia.
Journal: European journal of haematology
Published: December 16, 2020
Similar Doctors
Expertise in
43
conditions
Dr. Stephen Forman
Hematology | Oncology
Expertise in
43
conditions
Dr. Stephen Forman
Hematology | Oncology
Referral may be required

Stephen J. Forman, M.D.

1500 Duarte Rd, 
Duarte, CA 
 (9.6 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist practicing medicine in Duarte, California. Dr. Forman is highly rated in 43 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Pamela Becker, M.D., PH.D.

1500 Duarte Rd, 
Duarte, CA 
 (9.6 miles away)
800-826-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Pamela Becker is a Hematologist practicing medicine in Duarte, California. Dr. Becker is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, Bone Marrow Aspiration, and Colonoscopy.

Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology
Expertise in
10
conditions
Dr. Thomas Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (8.9 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Margaret O'donnell

How do I make an appointment with Dr. Margaret O'donnell?

You can book an appointment with Dr. Margaret O'donnell by calling their office at 626-359-8111. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Margaret O'donnell a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Margaret O'donnell is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Margaret O'donnell specialize in?

While Dr. Margaret O'donnell is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, and Acute Myeloblastic Leukemia with Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Margaret O'donnell participate in research or clinical trials?

Yes. Dr. Margaret O'donnell has published 26 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Margaret O'donnell's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Margaret O'donnell accept my insurance?

Dr. Margaret O'donnell accepts most major insurance plans, including Blue Shield of California and Humana. We recommend calling the office directly at 626-359-8111 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. O'donnell's expertise for a condition
ConditionClose
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile